AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31535609 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping
Number of subjects: 240
Study 30332542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (inputs and training for poultry farming and home gardening, and nutrition and health education)
Number of subjects: 500
Study 30332542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 500
Study 30332542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 26374114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + Morphine (0.5% bupivacaine 100 mg + morphine 2 mg)
Number of subjects: 240
Study 26374114 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine + Tenoxicam (0.5% bupivacaine 100 mg + tenoxicam 20 mg)
Number of subjects: 240
Study 25073008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral magnetic stimulation (SMS)
Number of subjects: 34
Study 25073008 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study 22469284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity cognitive behavioral intervention
Number of subjects: 0
Study 22469284 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 20645395 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning
Number of subjects: 0
Study 20645395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent clamping
Number of subjects: 0
Study 20645395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions (including antioxidants, anti-inflammatory drugs, vasodilators, pharmacological preconditioning, glucose infusion)
Number of subjects: 0
Study 17657865 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Chinese SF-36
Number of subjects: 150
Study 17657865 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Chinese SF-36
Number of subjects: 150
Study 15701468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 813
Study 15701468 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological therapy (loop diuretics, ACE inhibitors/ARBs, beta-blockers, spironolactone)
Number of subjects: 813
Study 12083314 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytostanol treatment (3 g/d in 3 servings)
Number of subjects: 12
Study 12083314 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 12
Study 12083314 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytostanol treatment
Number of subjects: 12
Study 10087722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 30 mg/day
Number of subjects: 50
Study 10087722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10087722 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 7488893 — intervention group
Group type: EXPERIMENTAL
Intervention: Two view mammography
Number of subjects: 40163
Study 7488893 — intervention group
Group type: COMPARATOR
Intervention: One view mammography
Number of subjects: 40163
Study 1971586 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol (0.2 mg kg‐1 by infusion over 5 min)
Number of subjects: 30
Study 1971586 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 30
Study 1971586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7408527 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen 400 mg, 3 times a day for 1 week
Number of subjects: 20
Study 7408527 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 1000 mg, 3 times a day for 1 week
Number of subjects: 20
Study 7408527 — intervention group
Group type: COMPARATOR
Intervention: Placebo during 2-day intervals
Number of subjects: 20
Study 31969363 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported computerised history taking (CHT) using a tablet.
Number of subjects: 2000
Study 31969363 — intervention group
Group type: COMPARATOR
Intervention: Standard history taking.
Number of subjects: 2000
Study 31039674 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower extremity VMRT training for 4 weeks
Number of subjects: 37
Study 31039674 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity VMRT training for 4 weeks
Number of subjects: 37
Study 31039674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 37
Study 28489495 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring suicide ideation
Number of subjects: 0
Study 28489495 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide protocol
Number of subjects: 0
Study 26500169 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART-CPT (hybrid treatment integrating CogSMART into cognitive processing therapy)
Number of subjects: 0
Study 26500169 — intervention group
Group type: COMPARATOR
Intervention: Standard CPT (Cognitive Processing Therapy)
Number of subjects: 0
Study 24186866 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2,000 mg/day)
Number of subjects: 20
Study 24186866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 20
Study 24186866 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Metformin and Sitagliptin
Number of subjects: 20
Study 24186866 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 22317067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention subjects (specific intervention details not provided)
Number of subjects: 0
Study 22317067 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 19205719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin four times per day in both eyes for at least 3 days
Number of subjects: 60
Study 19205719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levofloxacin for a minimum of 1 day
Number of subjects: 60
Study 19205719 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid scrub in addition to topical levofloxacin
Number of subjects: 60
Study 19205719 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 60
Study 17602062 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, 3.0 microg/kg every 2 weeks (Q2W)
Number of subjects: 285
Study 17602062 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 285
Study 15225585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500mg)
Number of subjects: 12
Study 15225585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400IU)
Number of subjects: 12
Study 15225585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and/or E
Number of subjects: 12
Study 15225585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E (combined)
Number of subjects: 12
Study 11687463 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (copolymer 1; Copaxone)
Number of subjects: 0
Study 11687463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9313670 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol
Number of subjects: 45
Study 9313670 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 45
Study 8184644 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 50
Study 8184644 — intervention group
Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 50
Study 8184644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 2967310 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 50 mg daily
Number of subjects: 38
Study 2967310 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 75 mg daily
Number of subjects: 38
Study 2967310 — intervention group
Group type: COMPARATOR
Intervention: Acitretin 10 mg daily
Number of subjects: 38
Study 2967310 — intervention group
Group type: COMPARATOR
Intervention: Acitretin 25 mg daily
Number of subjects: 38
Study 2967310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31743233 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg/day)
Number of subjects: 54
Study 31743233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 31157360 — intervention group
Group type: EXPERIMENTAL
Intervention: Active amyloid-β42 immunization (AN1792)
Number of subjects: 22
Study 31157360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 27748563 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit priming aimed at increasing positive expectations
Number of subjects: 36
Study 27748563 — intervention group
Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 36
Study 26515802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (<40 years)
Number of subjects: 53
Study 26515802 — intervention group
Group type: COMPARATOR
Intervention: Group B (≥40 years)
Number of subjects: 53
Study 24124176 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed erotic material (X-rated, soft-core magazines) provided during semen collection
Number of subjects: 1520
Study 24124176 — intervention group
Group type: COMPARATOR
Intervention: No printed erotic material provided during semen collection
Number of subjects: 1520
Study 22056247 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily, with possible increases to 7 mg and 10 mg)
Number of subjects: 723
Study 22056247 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 723
Study 22056247 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 723
Study 22056247 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 723
Study 19405825 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-submerged hollow cylindrical and solid-screw implants with titanium plasma-sprayed surface
Number of subjects: 192
Study 16461042 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pressure hemostasis after transfemoral coronary angiography
Number of subjects: 0
Study 16461042 — intervention group
Group type: COMPARATOR
Intervention: Discontinuing warfarin > or =48 hours before the procedure (INR <2.0)
Number of subjects: 0
Study 15759600 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplement (3.9 g total carbohydrates, 0.5 g glucose)
Number of subjects: 20
Study 15759600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10735262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials
Number of subjects: 0
Study 10735262 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-to-head comparisons
Number of subjects: 0
Study 8803518 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms per day in week 1, 1600 micrograms per day in week 2
Number of subjects: 9
Study 8803518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 750 micrograms per day in week 1, 1500 micrograms per day in week 2
Number of subjects: 9
Study 1611231 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 20
Study 1611231 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 20
Study 6373961 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit (low dose, 1.0 mg)
Number of subjects: 1922
Study 6373961 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit (high dose, 5.0 mg)
Number of subjects: 1922
Study 6373961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1922
Study 31685853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) paired with upper-limb rehabilitation
Number of subjects: 35
Study 31685853 — intervention group
Group type: COMPARATOR
Intervention: Control group (upper-limb rehabilitation without VNS)
Number of subjects: 35
Study 28742932 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated 12-Step facilitation (iTSF) treatment
Number of subjects: 59
Study 28742932 — intervention group
Group type: COMPARATOR
Intervention: Motivational enhancement therapy/cognitive-behavioral therapy (MET/CBT)
Number of subjects: 59
Study 26033801 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP plus IFN‐α‐2b (0.5 to 1.0 μg/kg per week subcutaneously, after chemotherapy until 2 years postregistration)
Number of subjects: 716
Study 26033801 — intervention group
Group type: COMPARATOR
Intervention: MAP alone
Number of subjects: 716
Study 26033801 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP plus IFN‐α‐2b
Number of subjects: 716
Study 22855233 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral robotic training
Number of subjects: 0
Study 22855233 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral robotic training
Number of subjects: 0
Study 22855233 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21479749 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac controlled porosity osmotic pump (CPOP) tablets (F4-34)
Number of subjects: 0
Study 21479749 — intervention group
Group type: COMPARATOR
Intervention: Commercial immediate-release Napilac® capsules
Number of subjects: 0
Study 19560810 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg golimumab
Number of subjects: 461
Study 19560810 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg golimumab
Number of subjects: 461
Study 19560810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 17710801 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20), Wangu (GB 12), and Tianzhu (BL 10) plus oral leech capsules and centipede capsules
Number of subjects: 30
Study 17710801 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of compound Danshen injection and oral aspirin
Number of subjects: 30
Study 15100686 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (dose not specified)
Number of subjects: 74
Study 11803060 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE (5log(10)PFU)
Number of subjects: 12
Study 11803060 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE (4log(10)PFU)
Number of subjects: 12
Study 11803060 — intervention group
Group type: COMPARATOR
Intervention: YF-VAX (5log(10)PFU)
Number of subjects: 12
Study 11803060 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-JE
Number of subjects: 12
Study 11803060 — intervention group
Group type: COMPARATOR
Intervention: ChimeriVax-JE and YF 17D
Number of subjects: 12
Study 10432262 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise protocol (daily performance of five shoulder exercises: two for stretching anterior shoulder musculature and three for strengthening posterior shoulder musculature)
Number of subjects: 42
Study 10432262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 42
Study 7580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with radical radiotherapy
Number of subjects: 9387
Study 7580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with supportive care
Number of subjects: 9387
Study 7580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 9387
Study 7580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy plus chemotherapy
Number of subjects: 9387
Study 7580546 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care plus chemotherapy
Number of subjects: 9387
Study 2024984 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.05%
Number of subjects: 533
Study 2024984 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.01%
Number of subjects: 533
Study 2024984 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.001%
Number of subjects: 533
Study 2024984 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.05%, 0.01%, 0.001%
Number of subjects: 533
Study 2024984 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 533
Study 6941670 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter identification task (L) in HT group
Number of subjects: 28
Study 6941670 — intervention group
Group type: COMPARATOR
Intervention: Letter identification task (L) in NT group
Number of subjects: 28
Study 6941670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic (MA) in HT group
Number of subjects: 28
Study 6941670 — intervention group
Group type: COMPARATOR
Intervention: Mental arithmetic (MA) in NT group
Number of subjects: 28
Study 6941670 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results in HT group
Number of subjects: 28
Study 6941670 — intervention group
Group type: COMPARATOR
Intervention: Overall results in NT group
Number of subjects: 28
Study 6322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane (weekly schedule: 1 gram per square meter BSA every 8 hours for two doses per week)
Number of subjects: 44
Study 6322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane (daily schedule: 250 mg per day)
Number of subjects: 44
Study 6322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane (weekly schedule)
Number of subjects: 44
Study 6322961 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus razoxane
Number of subjects: 44
Study 6322961 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 44
Study 31928507 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous aspiration with sclerotherapy (PAS) using 95% ethanol, n = 40
Number of subjects: 80
Study 31928507 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic marsupialization (LM) under general anesthesia, n = 40
Number of subjects: 80
Study 28771784 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine treatment intensifications
Number of subjects: 16
Study 28771784 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase de-escalation
Number of subjects: 16
Study 28771784 — intervention group
Group type: COMPARATOR
Intervention: Standard or experimental treatment
Number of subjects: 16
Study 28771784 — intervention group
Group type: COMPARATOR
Intervention: Physician's expertise
Number of subjects: 16
Study 26811171 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention
Number of subjects: 150
Study 26811171 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention
Number of subjects: 150
Study 26811171 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention satisfaction
Number of subjects: 150
Study 26811171 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication among multidisciplinary team
Number of subjects: 150
Study 24062200 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch
Number of subjects: 11
Study 24062200 — intervention group
Group type: COMPARATOR
Intervention: Control patch with low-dose capsaicin 0.075% cream
Number of subjects: 11
Study 22749368 — intervention group
Group type: COMPARATOR
Intervention: HDWL endoscopy
Number of subjects: 119
Study 22749368 — intervention group
Group type: EXPERIMENTAL
Intervention: HDWL + pCLE
Number of subjects: 119
Study 20416218 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound glycyrrhizin treatment
Number of subjects: 52
Study 20416218 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 52
Study 18713215 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient interdisciplinary rehabilitation program
Number of subjects: 11
Study 18713215 — intervention group
Group type: COMPARATOR
Intervention: Usual care (discharge back to the nursing home soon after surgery)
Number of subjects: 11
Study 15625362 — intervention group
Group type: EXPERIMENTAL
Intervention: TPZ/CIS (Tirapazamine and Cisplatin)
Number of subjects: 122
Study 15625362 — intervention group
Group type: COMPARATOR
Intervention: Chemoboost (Cisplatin and Fluorouracil)
Number of subjects: 122
Study 12536162 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism exposure
Number of subjects: 0
Study 12536162 — intervention group
Group type: COMPARATOR
Intervention: No prism exposure (baseline)
Number of subjects: 0
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli meal (300 g/d)
Number of subjects: 69
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Green peas meal (300 g/d)
Number of subjects: 69
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach meal (300 g/d)
Number of subjects: 69
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplemented meal (33.3 mg)
Number of subjects: 69
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Disruption of spinach matrix
Number of subjects: 69
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: All vegetable meals (broccoli, green peas, spinach)
Number of subjects: 69
Study 10655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli and green peas (per mg carotenoid consumed)
Number of subjects: 69
Study 8753922 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 60
Study 8753922 — intervention group
Group type: COMPARATOR
Intervention: McCoy blade
Number of subjects: 60
Study 1909469 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime
Number of subjects: 40
Study 1909469 — intervention group
Group type: COMPARATOR
Intervention: Interferon-gamma
Number of subjects: 40
Study 6874179 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handgrip at 30% of maximal voluntary contraction for 3 min
Number of subjects: 12
Study 6874179 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension at 30% of maximal voluntary contraction for 3 min
Number of subjects: 12
Study 30688872 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 13
Study 30688872 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study 29863280 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP14012 (10-320 mg single dose)
Number of subjects: 120
Study 29863280 — intervention group
Group type: EXPERIMENTAL
Intervention: DWP14012 (20-160 mg once daily for 7 days)
Number of subjects: 120
Study 29863280 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole (active comparator)
Number of subjects: 120